2.77

2.59% +0.07

After Hours: 2.79 0.02 +0.72%

VYNE Therapeutics Inc (VYNE)

Overview News Price History Financials Discussions Forecast Stock Split

VYNE Therapeutics Inc stock is currently priced at $2.77, with a 24-hour trading volume of 33,345. It has seen a +2.59% increased in the last 24 hours and a +15.42% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.74 pivot point. If it approaches the $2.81 resistance level, significant changes may occur.

Previous Close:

$2.70

Open:

$2.7

24h Volume:

33,345

Market Cap:

$40.24M

Revenue:

$424.00K

Net Income/Loss:

$-28.45M

P/E Ratio:

-0.2509

EPS:

-11.04

Net Cash Flow:

$-25.34M

1W Performance:

+3.75%

1M Performance:

+15.42%

6M Performance:

-29.16%

1Y Performance:

-61.42%

1D Range:

$2.70

$2.84

52W Range:

$1.67

$7.725

VYNE Therapeutics Inc Stock (VYNE) Company Profile

Name

VYNE Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

800 775 7936

Address

520 U.S. Highway 22, Suite 204, Bridgewater

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

VYNE's Discussions on Twitter

VYNE Therapeutics Inc Stock (VYNE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-21	Resumed	H.C. Wainwright	Buy

VYNE Therapeutics Inc Stock (VYNE) Latest News

Can VYNE Therapeutics Inc. (VYNE) Climb 415.04% to Reach the Level Wall Street Analysts Expect? - Yahoo Singapore News

Yahoo Singapore News

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

VYNE Therapeutics'(NASDAQ:VYNE) Share Price Is Down 11% Over The Past Year. - Yahoo Movies UK

Yahoo Movies UK

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates - Zacks Investment Research

Zacks Investment Research

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Defense World

VYNE Therapeutics Inc Stock (VYNE) Financials Data

VYNE Therapeutics Inc (VYNE) Revenue 2024

VYNE reported a revenue (TTM) of $424.00 thousand for the quarter ending December 31, 2023, a -11.11% decline year-over-year.

VYNE Therapeutics Inc (VYNE) Net Income 2024

VYNE net income (TTM) was -$28.45 million for the quarter ending December 31, 2023, a -22.59% decrease year-over-year.

VYNE Therapeutics Inc (VYNE) Cash Flow 2024

VYNE recorded a free cash flow (TTM) of -$25.34 million for the quarter ending December 31, 2023, a +13.22% increase year-over-year.

VYNE Therapeutics Inc (VYNE) Earnings per Share 2024

VYNE earnings per share (TTM) was -$7.2789 for the quarter ending December 31, 2023, a +1.50% growth year-over-year.

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.